×
About 1,002,963 results

A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis
https://clinicaltrials.gov/ct2/show/NCT02718300

Jan 14th, 2022 - The purpose of this study is to evaluate the safety, tolerability, and efficacy of the combination of parsaclisib and ruxolitinib in subjects with myelofibrosis.

A Study Evaluating The Efficacy And Safety Of Crovalimab Versus Eculizumab In Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors.
https://clinicaltrials.gov/ct2/show/NCT04432584

Jan 14th, 2022 - A study designed to evaluate the non-inferiority of crovalimab compared with eculizumab in participants with PNH currently treated with complement inhibitors. This study will enroll approximately 250 participants.

Safety and Efficacy Study of SAR442720 in Combination With Pembrolizumab in Advanced Malignancies
https://clinicaltrials.gov/ct2/show/NCT04418661

Jan 14th, 2022 - This open label Phase 1 multicenter study is designed to evaluate the safety and maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of SAR442720 in combination with pembrolizumab in participants with solid tumors in Part 1. In Part 2, in the expansion cohort (Cohort A) we will assess the antitumor activity and safety of SAR442720 combined with pembrolizumab in participants with me...

Triamcinolone Acetonide Injections in Mild-to-moderate Chronic Plaque Psoriasis With a Novel Needle-free Drug-delivery System
https://clinicaltrials.gov/ct2/show/NCT04410237

Jan 14th, 2022 - This is an observational pilot study comparing triamcinolone acetonide injections with the investigational Med-jet needle-free drug-delivery system as an alternative to using a conventional syringe and needle in patients with mild-to-moderate psoriasis. There will be five (5) visits necessary for study participation. The hypothesis is that the efficacy, safety, pain tolerance, and quality of li...

Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
https://clinicaltrials.gov/ct2/show/NCT04410523

Jan 14th, 2022 - This study is a phase IIb, multicenter, multi-national, double-blind, randomized, parallel-arm, placebo-controlled study to evaluate the effect of 5 dose levels of CSJ117 (0.5; 1; 2; 4 and 8 mg) inhaled once daily compared with placebo, when added to standard of care asthma therapy in adult subjects with inadequately controlled asthma despite medium to high dose ICS plus LABA. Approximately 625...

A Phase III Study Evaluating The Efficacy And Safety Of Crovalimab Versus Eculizumab In Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors.
https://clinicaltrials.gov/ct2/show/NCT04434092

Jan 14th, 2022 - A study designed to evaluate the non-inferiority of crovalimab compared with eculizumab in participants with PNH who have not been previously treated with complement inhibitor therapy. This study will enroll approximately 200 participants.

Targeted vs Standard Fortification of Breast Milk
https://clinicaltrials.gov/ct2/show/NCT03775785

Jan 14th, 2022 - Study design and setting This is a multi-centre superiority randomised parallel group, 1:1 allocation study. Patients will be recruited at three departments of neonatology and intensive care units: Department of Neonatology and Neonatal Intensive Care, Division of Neonatal Intensive Care (Medical University of Warsaw), and the Institute of Mother and Child. Follow up will be carried out at the ...

Midlines and Thrombophlebitis
https://clinicaltrials.gov/ct2/show/NCT03725293

Jan 14th, 2022 - Study Design The investigators propose a prospective single-site, parallel, two-arm, randomized investigation to assess catheter-related symptomatic upper extremity venous thrombosis (CR-UEVT), catheter-related bloodstream infection, and functionality of two single lumen midline catheters: AngioDynamics BioFlo 4 F and Teleflex Arrowg+ard Blue Advance 4.5 F. Research staff of Beaumont Health Ins...

Novel MRI Sequence- MR Fingerprinting
https://clinicaltrials.gov/ct2/show/NCT03722459

Jan 14th, 2022 - The purpose of this study is to evaluate novel quantitative MRI techniques in clinical studies to determine whether they can provide better, faster and more useful information for clinical diagnosis. In this study, the investigators propose to apply MR Fingerprinting and evaluate its performance for different diseases. These include, but are not limited to, diseases in the liver, kidney, cardia...

RACIN in Patients With Advanced TIL-negative Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT03728179

Jan 14th, 2022 - Subjects with locally advanced or metastatic incurable Tumor Infiltrating Lymphocytes (TIL)-negative solid tumors who are not eligible for, declined or failed standard therapy will be treated with a combination nivolumab, low-dose ionizing radiation (RT) (0.5-2 Gy), aspirin (ASA)(cohorts 1 and 2)/celecoxib (cohorts 3, 4 and Phase Ib), and either ipilimumab or low-dose cyclophosphamide. The stud...

Transcranial Direct Current Stimulation for Post-stroke Gait Rehab
https://clinicaltrials.gov/ct2/show/NCT03666533

Jan 14th, 2022 - Current rehabilitation methods fail to restore normal gait for many stroke survivors leading to dependence on others, recurrent falls, limitations in community ambulation and poor quality of life. The main objective of this study is to test both efficacy and neurophysiological mechanisms of a novel approach to treat persistent gait deficits after stroke with a combination of simultaneous non-in...

Rose Geranium in Sesame Oil Nasal Spray for the Improvement of Nasal Vestibulitis Symptoms in Cancer Patients Receiving Chemotherapy
https://clinicaltrials.gov/ct2/show/NCT04620369

Jan 14th, 2022 - PRIMARY OBJECTIVE: I. To determine the ability of rose geranium in sesame oil nasal spray to alleviate nasal vestibulitis in patients undergoing systemic, antineoplastic therapy when compared with isotonic nasal saline. SECONDARY OBJECTIVE: I. To assess toxicities related to rose geranium in sesame oil nasal spray in this study situation. OUTLINE: Patients are randomized to 1 of 2 arms. ARM A: ...

Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04639843

Jan 14th, 2022 - Background: T-cell lymphomas (TCLs) are a heterogeneous group of lymphoid malignancies defined by clonal proliferation of post-thymic T lymphocytes. Patients with newly diagnosed TCLs are most commonly treated with a CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone)-like regimen, with less than 30% having durable complete responses (CRs). Of the chemotherapy agents used, doxorubi...

STUDY OF TALAZOPARIB MONOTHERAPY IN CHINESE PARTICIPANTS WITH ADVANCED SOLID TUMORS
https://clinicaltrials.gov/ct2/show/NCT04635631

Jan 14th, 2022 - A phase1 study to evaluate the PK (single dose and multiple doses) and safety of talazoparib 1 mg Once Daily in Chinese adult participants with advanced solid tumors. A maximum of approximately 15 participants will be enrolled such that approximately 12 evaluable participants complete the study.

[Trial of device that is not approved or cleared by the U.S. FDA]
https://clinicaltrials.gov/ct2/show/NCT02907203

Jan 14th, 2022 - [Trial of device that is not approved or cleared by the U.S. FDA] - Full Text View.

Gut-Associated Lymphocyte Trafficking
https://clinicaltrials.gov/ct2/show/NCT02906137

Jan 14th, 2022 - Pathophysiological study in human subjects, comparative, national, multicentric and prospective. Peripheral blood and intestinal biopsies will be collected.

A Study To Investigate The Safety, Tolerability And Pharmacokinetics (PK) Of RO7223280 Following Intravenous Administration In Healthy Participants
https://clinicaltrials.gov/ct2/show/NCT04605718

Jan 14th, 2022 - The Study consists of 2 Parts: Part 1 (Single Ascending Dose/SAD) and Part 2 (Multiple Ascending Dose/MAD). Part 1 will investigate the safety, tolerability and PK of single-ascending intravenous (IV) doses of RO7223280 in healthy participants. Part 2 will investigate the safety, tolerability and PK of multiple-ascending IV doses of RO7223280 in healthy participants. Part 2 will only start afte...

Genotyping 2 SNPs in Chinese Breast Cancers
https://clinicaltrials.gov/ct2/show/NCT02886845

Jan 14th, 2022 - Since the 1990s breast cancers incidence of china has increased more than twice as fast as global rates. Chinese patients are responsible for 12.2% of all newly diagnosed breast cancers and 9.6% of all deaths to world breast cancers. Breast cancer is now the second frequently diagnosed cancer and is the leading cause of cancer-related death in Chinese women. Two of the most prevalent breast can...

A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
https://clinicaltrials.gov/ct2/show/NCT04687072

Jan 14th, 2022 - This is a phase 3, multicenter, randomized, double-blinded, placebo-controlled, parallel-group trial to evaluate the efficacy, safety, and effect on QoL/PRO of efgartigimod PH20 SC treatment in adult patients with primary ITP.

Unraveling the Mechanisms Underlying Primary Sclerosing Cholangitis Through a Multidisciplinary, Integrative Research Approach
https://clinicaltrials.gov/ct2/show/NCT04685200

Jan 14th, 2022 - In this single-site, small-scale prospective natural history study, we intend to recruit up to 40 patients with PSC diagnosed by standard clinical, biochemical, or imaging features (including up to 30 with a known diagnosis of IBD) and up to 90 controls. Evaluation of subjects with PSC and of controls, as well as all study related procedures will take place at the National Institutes of Health ...